107 related articles for article (PubMed ID: 27879229)
1. The Incidence of Ototoxicity in Patients Using Iron Chelators.
Derin S; Azık FM; Topal Y; Topal H; Karakuş V; Çetinkaya PU; Şahan M; Azık TE; Kocabaş CN
J Int Adv Otol; 2017 Apr; 13(1):136-139. PubMed ID: 27879229
[TBL] [Abstract][Full Text] [Related]
2. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
4. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
[TBL] [Abstract][Full Text] [Related]
5. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
6. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
7. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
Calvaruso G; Vitrano A; Di Maggio R; Lai E; Colletta G; Quota A; Gerardi C; Rigoli LC; Sacco M; Pitrolo L; Maggio A
Am J Hematol; 2015 Jul; 90(7):634-8. PubMed ID: 25809173
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
[TBL] [Abstract][Full Text] [Related]
9. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
[TBL] [Abstract][Full Text] [Related]
10. Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
Osma U; Kurtoglu E; Eyigor H; Yilmaz MD; Aygener N
Ear Nose Throat J; 2015 Dec; 94(12):481-5. PubMed ID: 26670754
[TBL] [Abstract][Full Text] [Related]
11. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
Haghpanah S; Zarei T; Zahedi Z; Karimi M
Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
[TBL] [Abstract][Full Text] [Related]
12. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia.
Mazza P; Amurri B; Lazzari G; Masi C; Palazzo G; Spartera MA; Giua R; Sebastio AM; Suma V; De Marco S; Semeraro F; Moscogiuri R
Haematologica; 1998 Jun; 83(6):496-501. PubMed ID: 9676021
[TBL] [Abstract][Full Text] [Related]
13. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.
Taher AT; Cappellini MD; Aydinok Y; Porter JB; Karakas Z; Viprakasit V; Siritanaratkul N; Kattamis A; Wang C; Zhu Z; Joaquin V; Uwamahoro MJ; Lai YR
Blood Cells Mol Dis; 2016 Mar; 57():23-9. PubMed ID: 26852651
[TBL] [Abstract][Full Text] [Related]
14. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
[TBL] [Abstract][Full Text] [Related]
15. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
Abdelrazik N
Hematology; 2007 Dec; 12(6):577-85. PubMed ID: 17852442
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
17. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy with deferoxamine and deferiprone.
Kattamis A
Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
[TBL] [Abstract][Full Text] [Related]
20. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
